Trial Profile
A Phase II Trial to Investigate Genetic Markers of Response to Pembrolizumab (MK-3475, SCH 900475) Combined With Chemotherapy as a First-line Treatment for Non-Small Cell Lung Cancer (KEYNOTE-782)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 May 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms KEYNOTE-782
- Sponsors Merck Sharp & Dohme Corp.
- 19 Apr 2023 Results assessing Response to first-line (1L) pembrolizumab plus chemotherapy in non-small cell lung cancer by blood tumor mutational burden presented at the 114th Annual Meeting of the American Association for Cancer Research
- 15 Nov 2021 Status changed from active, no longer recruiting to completed.
- 17 Aug 2021 Planned End Date changed from 10 Aug 2021 to 23 Aug 2023.